Global Gastroesophageal Reflux Disease Therapeutics Market

Gastroesophageal Reflux Disease Therapeutics Market Insights

Gastroesophageal reflux disease (GERD) is characterized by the reflux of stomach contents into the mouth via the oesophagus, resulting in a burning feeling behind the breastbone. Gastroesophageal reflux disease (GERD) is a common digestive ailment that affects the suppleness of the digestive system and lower oesophageal sphincter. Lifestyle modifications and unhealthy dietary patterns, as well as excessive intake of fatty meals, coffee, alcoholic drinks, citrus fruits, and pepper, cause gastroesophageal reflux disease. Excessive acid production causes gastroesophageal reflux disease, which destroys the lining of the stomach and eventually leads to ulcers. Other signs of gastroesophageal reflux disease comprise regurgitation and dysphagia. Coughing, sore throat, otitis media, chest discomfort, and enamel erosion or other dental indications are all common signs of aberrant reflux.

Acid reflux disorder can induce esophagitis, which is an inflammation of the oesophagus. Gastroesophageal reflux disease is caused by an imbalance between the oesophagus' regular resistance genes and aggressive components in the stomach, like acid and other digestive fluids and enzymes. Overconsumption of some drugs, like calcium channel blockers, nitrates, and antihistamines, can potentially induce gastroesophageal reflux disease.

GERD is a common recurring gastrointestinal illness that affects people all over the world. Over the previous decade, the global prevalence of acid reflux and accompanying symptoms has grown by approximately half i.e. 50%. This condition affects not only the health and quality of life of patients but also the health system and the business.

Gastroesophageal reflux disease (GERD) is a highly prevalent condition with a huge patient population. It affects people of all ages, from newborns to the elderly. The incidence of gastroesophageal reflux disease is on the rise all over the world. The ageing population is one of the factors contributing to the growth of the gastroesophageal reflux disease market. During the forecasted timeframe, the gastroesophageal reflux disease market is likely to be sustained by a rise in the number of patients being treated for gastroesophageal reflux disease and long-term anti-reflux conservation therapy. Constantly changing food habits and changes in lifestyle also influence the market for gastroesophageal reflux disease. While it’s all in the market's favor, there are certain inevitable restrictions, like patent expiration and a lackluster medication pipeline, that will limit the market's growth. Because there are so many medicines on the market for symptomatic therapy, the competition is fierce.

Some of the prominent factors driving the market are increasing consumption of junk food in the diet these days along with rising awareness about the treatment and therapies is also driving the market. This awareness is likely to be increased, which will drive the market during the predicted period. Moreover, improved healthcare facilities have also enabled the market to rise in the coming years. Furthermore, advancement in R&D activities in the medical and pharma industry coupled with increased technology and availability of modern therapies, treatments, and medicines will drive the market during the coming years.

Gastroesophageal Reflux Disease Therapeutics Market: By Drug Class

Based on the Drug Class, the Gastroesophageal Reflux Disease Therapeutics market can be segmented as Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), and Pro-kinetic agents. Antacids dominated the market in the past years and are expected to continue to do so during the projected period. Because antacids neutralize stomach acid discharges quickly, they are chosen as first-line treatment for moderate and infrequent problems. Antacids' widespread use is due to their easy over-the-counter accessibility in various forms like pills, powders, and syrups. Furthermore, the American Hospital Formulary, among other nations, promotes the use of over 120 antacid medications.

PPIs, the most widely recommended drug for indigestion, will make for the second-biggest portion. The introduction of generics following the loss of monopoly of popular medications such as Nexium and Prilosec have had an impact on branded PPI sales. With the pending expiration of additional patent-protected treatments, like Dexilant, a further decrease is predicted.

Gastroesophageal Reflux Disease Therapeutics Market: By Region

As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central &South America. Due to an older population and increased knowledge of pharmacological treatment, North America dominated the worldwide market for gastroesophageal reflux disease medications, followed by Europe. It is attributable to the existence of a big population of patients battling from heartburn and the availability of OTC generics. Moreover, due to improving healthcare infrastructure and the increased prevalence of GERD, the United States is likely to be the largest market. Tablet (chewable form) and liquid forms are the most popular in the United States

APAC region may have a detrimental influence on GERD in their everyday lives, as evidenced by the poor admission rate of treatment and the lower incidence of GERD in the region. Because of the balance between medicines and changes in lifestyle, the market for gastroesophageal reflux disease treatments in Japan will continue to develop.

The Middle East and African regions have a bright future in the worldwide gastroesophageal reflux disease therapeutics market, since foreign nations' healthcare spending is expanding, supporting new medication research.

Gastroesophageal Reflux Disease Therapeutics Market Share and Competitor Analysis

AstraZeneca, Addex Pharmaceuticals, Vecam, Medigus, Peer Medical, EndoGastric Solutions, Eisai Co., Ltd, Takeda Pharmaceutical Company Limited, RaQualia Pharma Inc, Reviva Pharmaceuticals Inc, Rottapharm Madaus, Torax Medical, and Mederi Therapeutics, among others, are the top players in the Gastroesophageal Reflux Disease Therapeutics Market.

Please note: This is not an exhaustive list of companies profiled in the report.

Poor retail sales and an extremely competitive generics-driven market are putting downward pressure on prescription costs, resulting in sluggish growth in the next years. Daewoong Pharmaceutical Co., Ltd., Ironwood Pharmaceuticals, Inc., SRS Pharmaceuticals Pvt. Ltd., and SFJ Pharmaceuticals Group are among the sector's newcomers.

Ironwood Pharmaceuticals, Inc. and RaQualia Pharma, Inc., for example, are concentrating on creating new generic compounds incorporating both existing and innovative therapeutic processes as part of their market-invasion strategy. Several generic players are also fighting for a greater market share by producing knockoff variants of blockbuster pharmaceuticals to replace those that have expired.